Ipratropium
Atrovent, Combivent (ipratropium) is a small molecule pharmaceutical. Ipratropium was first approved as Atrovent on 1986-12-29. It is used to treat allergic rhinitis perennial, bronchial spasm, bronchitis, pulmonary emphysema, and vasomotor rhinitis in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M5, muscarinic acetylcholine receptor M1, and muscarinic acetylcholine receptor M4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Atrovent (generic drugs available since 2001-01-26)
CombinationsCombivent (generic drugs available since 2001-01-26, discontinued: Duoneb)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Albuterol sulfate
+
Ipratropium bromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COMBIVENT RESPIMAT | Boehringer Ingelheim | N-021747 RX | 2011-10-07 | 1 products, RLD, RS |
Show 2 discontinued
Ipratropium bromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ATROVENT HFA | Boehringer Ingelheim | N-021527 RX | 2004-11-27 | 1 products, RLD, RS |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| albuterol sulfate | 2008-09-09 | |
| atrovent | New Drug Application | 2023-10-05 |
| atrovent hfa | 2007-07-26 | |
| atroventhfa | New Drug Application | 2010-07-28 |
| combivent respimat | New Drug Application | 2023-05-23 |
| duoneb | ANDA | 2012-10-26 |
| ipratropium bromide | ANDA | 2024-01-30 |
| ipratropium bromide and albuterol sulfate | ANDA | 2024-01-30 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Albuterol Sulfate / Ipratropium Bromide, Combivent Respimat, Boehringer Ingelheim | |||
| 8733341 | 2030-10-16 | DP | |
| 7837235 | 2028-03-13 | DP | |
| 9027967 | 2027-03-31 | DP | |
| 7396341 | 2026-10-10 | DP | |
| 7896264 | 2025-05-26 | DP | |
| 7284474 | 2024-08-26 | DP | |
| Ipratropium Bromide, Atrovent Hfa, Boehringer Ingelheim | |||
| 8474447 | 2030-01-17 | DP | |
ATC Codes
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AX: Other nasal preparations in atc
— R01AX03: Ipratropium bromide
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AL: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
— R03AL01: Fenoterol and ipratropium bromide
— R03AL02: Salbutamol and ipratropium bromide
— R03B: Other drugs for obstructive airway diseases, inhalants in atc
— R03BB: Anticholinergics inhalants for obstructive airway diseases
— R03BB01: Ipratropium bromide
HCPCS
Code | Description |
|---|---|
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
| J7645 | Ipratropium bromide, inhalation solution, compounded product, administered through dme, unit dose form, per milligram |
Clinical
Clinical Trials
178 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 5 | 12 | 24 | 23 | 39 | 103 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 2 | 8 | 14 | 15 | 40 |
| Disease progression | D018450 | — | — | — | — | 1 | 3 | 3 | 7 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | — | 1 | 1 | 1 | — | 3 |
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | — | — | 1 | 2 | 3 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | — | — | 1 | — | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | 1 | — | 1 |
| Cold temperature | D003080 | — | — | — | — | — | 1 | — | 1 |
| Exercise-induced asthma | D001250 | — | J45.990 | — | — | — | 1 | — | 1 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Status asthmaticus | D013224 | — | — | 1 | 2 | 1 | — | 2 | 5 |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | — | 2 | 1 | — | — | 2 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | — | 1 | — | — | 1 |
| Familial dysautonomia | D004402 | Orphanet_1764 | G90.1 | — | — | 1 | — | — | 1 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute lung injury | D055371 | EFO_0004610 | — | — | 1 | — | — | 1 | 2 |
| Sialorrhea | D012798 | HP_0002307 | K11.7 | — | 1 | — | — | 1 | 2 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | — | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | 1 | 3 |
| Depression | D003863 | — | F33.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Common cold | D003139 | EFO_0007214 | J00 | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Interstitial lung diseases | D017563 | HP_0006530 | J84.89 | — | — | — | — | 1 | 1 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 1 | 1 |
| Quadriplegia | D011782 | HP_0002510 | G82.5 | — | — | — | — | 1 | 1 |
| Anesthesia | D000758 | — | — | — | — | — | — | 1 | 1 |
| Thoracotomy | D013908 | — | — | — | — | — | — | 1 | 1 |
| Critical care | D003422 | — | — | — | — | — | — | 1 | 1 |
| Bronchitis | D001991 | — | J40 | — | — | — | — | 1 | 1 |
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ipratropium |
| INN | ipratropium bromide |
| Description | Ipratropium bromide is the anhydrous form of the bromide salt of ipratropium. An anticholinergic drug, ipratropium bromide blocks the muscarinic cholinergic receptors in the smooth muscles of the bronchi in the lungs. This opens the bronchi, so providing relief in chronic obstructive pulmonary disease and acute asthma. It has a role as a bronchodilator agent, a muscarinic antagonist and an antispasmodic drug. It contains an ipratropium. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives; atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2 |
Identifiers
| PDB | — |
| CAS-ID | 60205-81-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1621597 |
| ChEBI ID | — |
| PubChem CID | 657308 |
| DrugBank | DBSALT002739 |
| UNII ID | VJV4X1P2Z1 (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
CHRM2
CHRM2
CHRM5
CHRM5
CHRM1
CHRM1
CHRM4
CHRM4
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Ipratropium
+
Albuterol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Ipratropium
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,821 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,502 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use